The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses

The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses
Executive summary 12

Industry overview 12

Cipla 13

Ranbaxy 13

GSK (India) 14

Piramal Healthcare 14

Zydus Cadila 15

Sun Pharma 15

Lupin Laboratories (Lupin) 16

Alkem 16

Sanofi-Aventis (India) 17

Mankind Pharma (Mankind) 17

Chapter 1 Introduction 20

What is this report about? 20

Methodology 20

Chapter 2 Industry overview 24

Summary 24

Introduction 25

Market dynamics 25

Indian pharmaceutical market: size and growth 25

Key market drivers and resistors 26

India's adoption of product patent regime 27

Evolution of biopharmaceuticals in India 28

Competitive positioning of India in global pharmaceutical market 30

Competitive landscape 32

Competitive positioning of the top 10 companies 32

Exposure to US generics market 35

Comparative analysis of the top 10 companies 36

Trends 37

Increasing participation of innovator companies in Indian pharmaceutical space 37

Pharmaceutical companies making inroads into rural India 38

Shifting focus towards Japanese generics market 39

Growing prevalence of lifestyle diseases 40

Expanding alliances in biopharmaceuticals 41

Chapter 3 Cipla 46

Summary 46

Company overview 47

Marketed products 47

Therapeutic focus 49

Research and development 49

Growth strategies 50

Expanding in international markets through alliances and partnerships 50

Expanding capabilities 50

Growing in the US generics market 51

Acquisitions and divestments 51

SWOT analysis 52

Chapter 4 Ranbaxy 54

Summary 54

Company overview 55

Marketed products 56

Therapeutic focus 56

Research and development 57

Growth strategies 58

Rebuilding business in the US market 58

Shifting focus towards complex products in the US 58

Monetizing the FTF opportunities in the US 58

Improving penetration in emerging markets 59

Strengthening management involvement in Ranbaxy 59

Acquisitions and divestments 60

SWOT analysis 61

Chapter 5 GSK (India) 64

Summary 64

Company overview 65

Marketed products 66

Therapeutic focus 66

Research and development 67

Growth strategies 68

Augmenting product portfolio in India 68

Leveraging its parent company's product portfolio 68

In-licensing products 69

Expanding rural presence and hospital sales 69

Acquisitions and divestments 70

SWOT analysis 71

Chapter 6 Piramal Healthcare 74

Summary 74

Company overview 75

Marketed products 75

Therapeutic focus 77

Research and development 77

Growth strategies 78

Capitalize on contract manufacturing opportunities 78

Growing business through alliances and partnerships 78

Acquisitions and divestments 79

SWOT analysis 81

Chapter 7 Zydus Cadila 84

Summary 84

Company overview 85

Marketed products 86

Therapeutic focus 86

Research and development 87

Growth strategies 88

Alliances fostering growth in international generics markets 88

Sustaining revenue growth in Indian formulation business 89

Acquisitions and divestments 90

SWOT analysis 91

Chapter 8 Sun Pharma 94

Summary 94

Company overview 95

Marketed products 95

Therapeutic focus 97

Research and development 97

Growth strategies 98

Enhancing presence in the US market 98

Focusing on niche segments in developing markets 98

Plugging gaps in its business through investments 99

Acquisitions and divestments 99

SWOT analysis 100

Chapter 9 Lupin 102

Summary 102

Company overview 103

Marketed products 103

Therapeutic focus 104

Research and development 104

Growth strategies 105

Expanding in European markets 105

Foray into biosimilars market 105

Sustaining growth in the US generics market 106

Shifting focus to chronic and specialized products in India 106

Acquisitions and divestments 106

SWOT analysis 108

Chapter 10 Alkem 110

Summary 110

Company overview 111

Marketed products 111

Therapeutic focus 112

Research and development 112

Growth strategies 113

Expanding presence in nutraceuticals business 113

Expansion in international markets 113

Acquisitions and divestments 114

SWOT analysis 114

Chapter 11 Sanofi-Aventis (India) 116

Summary 116

Company overview 117

Marketed products 117

Therapeutic focus 118

Research and development 119

Growth strategies 119

Leveraging parent company's product portfolio 119

Shifting focus to rural India 120

Acquisitions and divestments 121

SWOT analysis 122

Chapter 12 Mankind 124

Summary 124

Company overview 125

Marketed products 126

Therapeutic focus 126

Research and development 127

Growth strategies 128

Expanding in international markets 128

Investing in pharmaceutical capabilities development 128

Foray into fast growing segments 128

Acquisitions and divestments 129

SWOT analysis 130

Chapter 13 11-20 companies 132

Abbott (India) 132

Company overview 132

Marketed products 133

Therapeutic focus 134

Research and development 134

Dr Reddy's 135

Company overview 135

Marketed products 136

Therapeutic focus 137

Research and development 138

Wockhardt 139

Company overview 139

Marketed products 140

Therapeutic focus 140

Research and development 141

Aristo 142

Company overview 142

Marketed products 143

Therapeutic focus 144

Torrent Pharmaceuticals (Torrent) 145

Company overview 145

Marketed products 146

Therapeutic focus 147

Research and development 147

Pfizer (India) 148

Company overview 148

Marketed products 149

Therapeutic focus 150

Research and development 151

Intas 151

Company overview 151

Marketed products 152

Therapeutic focus 152

Research and development 153

Alembic 154

Company overview 154

Marketed products 155

Therapeutic focus 155

Research and development 156

FDC 157

Company overview 157

Marketed products 157

Therapeutic focus 158

Research and development 159

Macleods Pharmaceuticals (Macleods) 160

Company overview 160

Marketed products 161

Therapeutic focus 162

Research and development 162

Chapter 14 Appendix 164

Glossary 164

Index 168

List of Figures

Figure 2.1: Indian pharmaceutical market size ($m), 2009-14 26

Figure 2.2: Key market drivers and resistors of Indian pharmaceutical market 27

Figure 2.3: Indian pharmaceutical market SWOT analysis 30

Figure 2.4: Top 10 pharmaceutical companies in India market share, 2008 33

Figure 2.5: Top 10 pharmaceutical companies in India growth, 2004-08 34

Figure 2.6: Comparative analysis of the top Indian pharmaceutical companies 37

Figure 2.7: Top 10 pharmaceutical companies in India lifestyle segment market share (%), 2008 41

Figure 3.8: Cipla therapeutic focus, 2007-08 49

Figure 3.9: Cipla SWOT analysis 52

Figure 4.10: Ranbaxy therapeutic focus, 2007-08 57

Figure 4.11: Ranbaxy SWOT analysis 61

Figure 5.12: GSK (India) therapeutic focus, 2007-08 67

Figure 5.13: GSK (India) SWOT analysis 71

Figure 6.14: Piramal Healthcare therapeutic focus, 2007-08 77

Figure 6.15: Piramal Healthcare SWOT analysis 81

Figure 7.16: Zydus Cadila therapeutic focus, 2007-08 87

Figure 7.17: Zydus Cadila SWOT analysis 91

Figure 8.18: Sun Pharma therapeutic focus, 2007-08 97

Figure 8.19: Sun Pharma SWOT analysis 100

Figure 9.20: Lupin therapeutic focus, 2007-08 104

Figure 9.21: Lupin SWOT analysis 108

Figure 10.22: Alkem therapeutic focus, 2007-08 112

Figure 10.23: Alkem SWOT analysis 114

Figure 11.24: Sanofi-Aventis (India) therapeutic focus, 2007-08 119

Figure 11.25: Sanofi-Aventis (India) SWOT analysis 122

Figure 12.26: Mankind therapeutic focus, 2007-08 127

Figure 12.27: Mankind SWOT analysis 130

Figure 13.28: Abbott (India) therapeutic focus, 2007-08 134

Figure 13.29: Dr Reddy's therapeutic focus, 2007-08 137

Figure 13.30: Wockhardt therapeutic focus, 2007-08 141

Figure 13.31: Aristo therapeutic focus, 2007-08 144

Figure 13.32: Torrent therapeutic focus, 2007-08 147

Figure 13.33: Pfizer (India) therapeutic focus, 2007-08 150

Figure 13.34: Intas therapeutic focus, 2007-08 153

Figure 13.35: Alembic therapeutic focus, 2007-08 156

Figure 13.36: FDC therapeutic focus, 2007-08 159

Figure 13.37: Macleods therapeutic focus, 2007-08 162

List of Tables

Table 2.1: Indian pharmaceutical market size ($m), 2009-14 25

Table 2.2: Novel product pipeline of select Indian biotechnology companies, 2008 29

Table 2.3: Major foreign acquisitions by Indian pharmaceutical companies, 2007-09 32

Table 2.4: Top 10 pharmaceutical companies in India growth (%), 2004-08 34

Table 2.5: Selected ANDA filings approved in the US, 2009 35

Table 2.6: Deals and alliances in Japanese pharmaceutical market, 2007-09 40

Table 2.7: Selected alliances in the Indian biopharmaceutical market, 2007-09 43

Table 3.8: Cipla snapshot 46

Table 3.9: Cipla top 10 marketed products sales ($m), 2007-08 47

Table 3.10: Cipla new product launches, 2007-08 48

Table 3.11: Approved ANDAs of Cipla in the US, 2007-09 51

Table 4.12: Ranbaxy snapshot 54

Table 4.13: Ranbaxy top 10 marketed products sales in India ($m), 2007-08 56

Table 4.14: Selected Ranbaxy ANDAs with FTF status 59

Table 4.15: Ranbaxy acquisitions, 2007-09 60

Table 5.16: GSK (India) snapshot 64

Table 5.17: GSK (India) top 10 marketed products sales ($m), 2007-08 66

Table 5.18: GSK (India) product launches from parent portfolio, 2007-09 68

Table 5.19: GSK (India) expected new launches in India, 2009-10. 69

Table 6.20: Piramal Healthcare snapshot 74

Table 6.21: Piramal Healthcare top 10 marketed products sales ($m), 2007-08 76

Table 6.22: Piramal Healthcare new product launches, 2007-08 76

Table 6.23: Select Piramal Healthcare's alliances, 2007-09 79

Table 6.24: Piramal Healthcare acquisitions, 2007-09 80

Table 7.25: Zydus Cadila snapshot 84

Table 7.26: Zydus Cadila top 10 marketed products sales ($m), 2007-08 86

Table 7.27: Zydus Cadila R&D collaborations, 2007-09 88

Table 7.28: Select Zydus Cadila's alliances, 2005-09 89

Table 7.29: Zydus Cadila acquisitions, 2007-09 90

Table 8.30: Sun Pharma snapshot 94

Table 8.31: Sun Pharma top 10 marketed products sales ($m), 2007-08 95

Table 8.32: Sun Pharma new product launches, 2007-08 96

Table 9.33: Lupin snapshot 102

Table 9.34: Lupin top 10 marketed products sales ($m), 2007-08 103

Table 9.35: Lupin acquisitions, 2007-09 107

Table 10.36: Alkem snapshot 110

Table 10.37: Alkem top 10 marketed products sales ($m), 2007-08 111

Table 11.38: Sanofi-Aventis (India) snapshot 116

Table 11.39: Sanofi-Aventis (India) top 10 marketed products sales ($m), 2007-08 118

Table 11.40: Sanofi-Aventis (India) key brands launches from parent portfolio 120

Table 12.41: Mankind snapshot 124

Table 12.42: Mankind top 10 marketed products sales ($m), 2007-08 126

Table 13.43: Abbott (India) snapshot 132

Table 13.44: Abbott (India) top 10 marketed products sales ($m), 2007-08 133

Table 13.45: Dr Reddy's snapshot 135

Table 13.46: Dr Reddy's top 10 marketed products sales ($m), 2007-08 136

Table 13.47: Dr Reddy's drug development pipeline, 2007-08 138

Table 13.48: Wockhardt snapshot 139

Table 13.49: Wockhardt top 10 marketed products sales ($m), 2007-08 140

Table 13.50: Aristo snapshot 142

Table 13.51: Aristo top 10 marketed products sales ($m), 2007-08 143

Table 13.52: Torrent snapshot 145

Table 13.53: Torrent top 10 marketed products sales ($m), 2007-08 146

Table 13.54: Pfizer (India) snapshot 148

Table 13.55: Pfizer (India) top 10 marketed products sales ($m), 2007-08 149

Table 13.56: Intas snapshot 151

Table 13.57: Intas top 10 marketed products sales ($m), 2007-08 152

Table 13.58: Alembic snapshot 154

Table 13.59: Alembic top 10 marketed products sales ($m), 2007-08 155

Table 13.60: FDC snapshot 157

Table 13.61: FDC top 10 marketed products sales ($m), 2007-08 158

Table 13.62: Selected FDC new product launches, 2007-08 158

Table 13.63: Macleods snapshot 160

Table 13.64: Macleods top 10 marketed products sales($m), 2007-08 161